Illumina, Inc. (NASDAQ:ILMN) – Investment analysts at First Analysis raised their Q4 2017 earnings per share estimates for shares of Illumina in a research note issued on Wednesday, according to Zacks Investment Research. First Analysis analyst T. Marshbanks now anticipates that the life sciences company will post earnings of $1.18 per share for the quarter, up from their prior estimate of $1.09. First Analysis currently has a “Equal Weight” rating and a $176.00 target price on the stock.
ILMN has been the subject of a number of other research reports. Barclays PLC upped their price objective on shares of Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, October 25th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $229.00 price objective for the company in a report on Friday, October 27th. Canaccord Genuity reissued a “buy” rating and issued a $230.00 price objective (up previously from $215.00) on shares of Illumina in a report on Thursday, October 12th. BidaskClub lowered shares of Illumina from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 25th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $226.00 price objective (up previously from $202.00) on shares of Illumina in a report on Monday, October 9th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $200.88.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://ledgergazette.com/2017/11/13/q4-2017-eps-estimates-for-illumina-inc-boosted-by-first-analysis-ilmn.html.
Shares of Illumina (NASDAQ:ILMN) traded down $0.67 on Friday, hitting $208.94. 598,500 shares of the company were exchanged, compared to its average volume of 805,341. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. Illumina has a 12-month low of $119.37 and a 12-month high of $214.50. The stock has a market capitalization of $30,505.24, a price-to-earnings ratio of 61.09, a P/E/G ratio of 3.45 and a beta of 0.74.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. Illumina had a net margin of 21.29% and a return on equity of 23.48%. The firm had revenue of $714.00 million during the quarter, compared to analyst estimates of $692.77 million. During the same quarter in the prior year, the firm posted $0.97 earnings per share. Illumina’s quarterly revenue was up 17.6% on a year-over-year basis.
In related news, Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $194.73, for a total value of $3,894,600.00. Following the sale, the director now owns 539,176 shares of the company’s stock, valued at $104,993,742.48. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Michel Bouchard sold 616 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,200.00. Following the completion of the sale, the chief accounting officer now directly owns 15,161 shares in the company, valued at approximately $3,032,200. The disclosure for this sale can be found here. In the last ninety days, insiders sold 187,964 shares of company stock worth $38,454,069. 1.60% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in ILMN. Winslow Capital Management LLC acquired a new stake in Illumina during the second quarter worth approximately $211,584,000. HPM Partners LLC raised its holdings in Illumina by 29,103.8% during the second quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock worth $107,724,000 after purchasing an additional 749,424 shares in the last quarter. Fred Alger Management Inc. raised its holdings in Illumina by 611.9% during the second quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock worth $110,636,000 after purchasing an additional 548,030 shares in the last quarter. TIAA CREF Investment Management LLC raised its holdings in Illumina by 55.6% during the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after purchasing an additional 527,548 shares in the last quarter. Finally, Capital World Investors raised its holdings in Illumina by 23.8% during the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after purchasing an additional 410,000 shares in the last quarter. 93.07% of the stock is currently owned by institutional investors.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.